Rinvoq

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
Fierce Pharma
AbbVie
Rinvoq
patents
legal
Sandoz
Sun Pharma
Intas Pharmaceuticals
Flag link:
AbbVie and Lupus Therapeutics partner for SLE trial recruitment
AbbVie and Lupus Therapeutics partner for SLE trial recruitment
Clinical Trials Arena
AbbVie
Lupus Therapeutics
systemic lupus erythematosus
lupus
Rinvoq
clinical trials
Flag link:
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
Clinical Trials Arena
AbbVie
clinical trials
Rinvoq
atopic dermatitis
Flag link:
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Xtalks
pharma advertising
DTC ads
AbbVie
Skyrizi
Rinvoq
Regeneron
Flag link:
AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
Fierce Pharma
AbbVie
Rinvoq
Humira
systemic lupus erythematosus
lupus
clinical trials
Flag link:
AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease
AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease
Fierce Pharma
AbbVie
FDA
Rinvoq
Crohn's Disease
Humira
Flag link:
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
AbbVie
Skyrizi
ulcerative colitis
lupus
Rinvoq
clinical trials
Flag link:
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
Endpoints
AbbVie
Humira
Rinvoq
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
BioPharma Dive
JPMHC 2023
AbbVie
Richard Gonzalez
Pharma CEOs
Humira
Skyrizi
Rinvoq
Flag link:
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
BioSpace
AbbVie
cedirogant
Skyrizi
Rinvoq
Humira
Flag link:
Where Will AbbVie Be in 3 Years?
Where Will AbbVie Be in 3 Years?
Motley Fool
AbbVie
Humira
biosimilars
Rinvoq
Skyrizi
Vraylar
Flag link:
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
Motley Fool
Rinvoq
AbbVie
Europe
ulcerative colitis
Flag link:
AbbVie Redeems Priority Review Voucher for Rinvoq Approval
AbbVie Redeems Priority Review Voucher for Rinvoq Approval
BioSpace
AbbVie
Rinvoq
priority review
priority review vouchers
ulcerative colitis
Flag link:
Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s
Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s
Pharmaforum
AbbVie
Rinvoq
clinical trials
Crohn’s disease
Flag link:
AbbVie's red-hot Rinvoq scores fourth FDA approval in five months
AbbVie's red-hot Rinvoq scores fourth FDA approval in five months
Fierce Pharma
AbbVie
Rinvoq
FDA
ankylosing spondylitis
Flag link:
Ahead of Humira's patent cliff, AbbVie's Rinvoq notches third new use in 4 months
Ahead of Humira's patent cliff, AbbVie's Rinvoq notches third new use in 4 months
Fierce Pharma
AbbVie
Rinvoq
ulcerative colitis
FDA
Flag link:
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
AbbVie
earnings
Rick Gonzalez
Skyrizi
Rinvoq
Flag link:
What This FDA News Could Mean for AbbVie's Stock
What This FDA News Could Mean for AbbVie's Stock
Motley Fool
AbbVie
Rinvoq
FDA
Flag link:
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
AbbVie
Rinvoq
Skyrizi
JPMHC 2022
Flag link:

Pages